tirzepatide heart failure fda 2025 ACC Scientific Statement on the Management of Obesity in Adults With Failure: A Report of the American College of Cardiology GLP-1 Medications for Weight Loss:

To the Editor: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common diverse X-linked human enzymopathy genetic trait

When used with insulin or sulfonylureas, there is an increased risk of hypoglycemia that may necessitate dose adjustments of these medications

For patients that are expecting an upcoming surgery, the use of Rybelsus should be disclosed as it could cause complications

Create a replacement plan

of Med+ members given the GLP-1 Success Program say it helped minimize side effects* increase in quality of life was experienced by Med+ members given the GLP-1 Success Program** weight loss among WW Med+ members given the GLP-1 Success Program, on average, after 6 months*** *Based on survey responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/tirzepatide for weight loss within the WW Clinic Program and participating in the GLP-1 companion nutrition program

Journal of Neuroscience , 30 (44), 14630-14634